
InflaRx (IFRX) Stock Forecast & Price Target
InflaRx (IFRX) Analyst Ratings
Bulls say
InflaRx is a biopharmaceutical company with promising product candidates targeting C5a and its receptor C5aR to treat various autoimmune and inflammatory diseases. Management is actively discussing options for advancing their lead asset izicopan towards ANCA-associated vasculitis, which could have a significant impact on the company's market potential. The company has also highlighted potential opportunities for izicopan in other renal diseases, such as IgA Nephropathy, and has spoken of a possible renal basket trial. With a robust pipeline and potential for partnerships and collaborations, InflaRx has a strong outlook in the biopharmaceutical industry.
Bears say
InflaRx is facing risks in their clinical development plans for izicopan, an anti-C5a monoclonal antibody, in the treatment of AAV due to potential difficulties in study design and enrollment criteria. Additionally, their potential dosing strategy of 60 mg BID may not be optimal, and they likely won't conduct a head-to-head study against AMGN's Tavneos, suggesting potential for inferior efficacy compared to the currently-marketed drug. Furthermore, there are concerns about Tavneos' safety profile and potential withdrawal from the market, leading to conservative valuation estimates and a negative outlook on InflaRx's stock.
This aggregate rating is based on analysts' research of InflaRx and is not a guaranteed prediction by Public.com or investment advice.
InflaRx (IFRX) Analyst Forecast & Price Prediction
Start investing in InflaRx (IFRX)
Order type
Buy in
Order amount
Est. shares
0 shares